Lawrence Corey
Overview
Explore the profile of Lawrence Corey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
506
Citations
22559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi N, et al.
EClinicalMedicine
. 2025 Feb;
80:103054.
PMID: 39902315
Background: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008...
2.
Omole T, Nguyen H, Marcinow A, Oo M, Jahan N, Ssemaganda A, et al.
J Infect Dis
. 2024 Dec;
PMID: 39720913
Background: CD4+ T cells expressing α4β7 are optimal targets for HIV infections, with higher pre-HIV α4β7hi expression linked to increased HIV acquisition and progression in South African women. However, similar...
3.
Ellison S, Hayman I, Derr K, Derr P, Frebert S, Itkin Z, et al.
bioRxiv
. 2024 Dec;
PMID: 39713402
Herpes simplex virus (HSV) infection has worldwide public health concerns and lifelong medical impacts. The standard therapy, acyclovir, has limited efficacy in preventing HSV subclinical virus shedding, and drug resistance...
4.
Wilson G, Church L, Kelley C, Robinson S, Lu Y, Furch B, et al.
J Infect Dis
. 2024 Dec;
PMID: 39671174
Utilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced...
5.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
6.
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, et al.
medRxiv
. 2024 Nov;
PMID: 39484284
Background: The neonatal immune system is uniquely poised to generate broadly neutralizing antibodies (bnAbs) and thus infants are ideal for evaluating HIV vaccine candidates. We present the design and safety...
7.
Zhang B, Fong Y, Fintzi J, Chu E, Janes H, Kenny A, et al.
Nat Commun
. 2024 Sep;
15(1):7954.
PMID: 39261482
In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection...
8.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine
. 2024 Sep;
108:105320.
PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
9.
Hahn W, Parks K, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, et al.
J Exp Med
. 2024 Sep;
221(10).
PMID: 39235529
Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140...
10.
Janes H, Fisher L, Kee J, Parameswaran L, Goepfert P, Falsey A, et al.
J Infect Dis
. 2024 Sep;
230(6):1384-1389.
PMID: 39225478
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in...